Scientists test cancer drug safety in people with liver problems
NCT ID NCT06352528
Summary
This study measured how a single dose of the cancer drug repotrectinib behaves in people with moderate or severe liver impairment compared to healthy people. Researchers enrolled 18 adults to understand if liver problems change how the drug moves through the body. The goal was to gather safety and dosing information for future use in patients with both cancer and liver issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014-2811, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.